ERBB2 and neoplasm: For example, the KATHERINE trial demonstrated the importance of assessing tumour response post-neoadjuvant therapy in HER2+ patients, with adjuvant trastuzumab-emtansine (T-DM1) improving outcomes in those with residual disease [4].